18 results about "Dosing schedules" patented technology

A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and / or 12 weeks.

Provided herein are pharmaceutical formulations of a therapeutically effective amount of (R)-N-(1-hydroxypropyl-2-yl)-5-(4-(trifluoromethyl) phenoxy)-2-naphthamide in a solid dosage form. Also provided herein are methods of treating cancer comprising a pharmaceutical formulation of a therapeutically effective amount of (R)-N-(1-hydroxypropyl-2-yl)-5-(4-(trifluoromethyl) phenoxy)-2-naphthamide in a solid dosage form.

Exemplary embodiments relate to automated medicament delivery (AMD) devices. Such devices may measure the level of an analyte and deliver medicament with the intent of maintaining the analyte at a target level or in a target range. The described methods and apparatuses apply a model to evaluate an effect of proposed future medicament doses on predicted analyte levels. The proposed future medicament doses and predicted analyte levels may be supplied to a cost function to select which of the proposed future medicament dose schedules results in optimal control of the predicted analyte levels. The cost function may apply a weighting scheme that weighs predictions in the near- and / or medium-term future more than longer-term predictions.

Embodiments of the invention relate to methods of treating multiple myeloma in a subject in need thereof, the method comprising administering to the subject a BCMAxCD3 bispecific antibody on a monthly dosing schedule.

To provide a therapeutic and / or prophylactic agent for mycosis, which is excellent in safety and effectiveness, is administered to a Japanese mycosis patient, and contains isavuconazole or a prodrug thereof as an active ingredient.SOLUTION: A therapeutic and / or prophylactic agent for mycosis, which is administered according to a loading dosing regimen, and further administered according to a maintenance dosing regimen after a lapse of 12 to 24 hours from the end of the loading dosing regimen. (1) Loading dosing schedule: a dosing schedule in which isavuconazole or a pro-drug thereof is administered in 200mg by oral administration or intravenous drip infusion every 8 hours for a total of 6 times (2) Maintenance dosing schedule: a dosing schedule in which isavuconazole or a pro-drug thereof is administered in 200mg by oral administration or intravenous drip infusion once a day in terms of isavuconazole per dose.SELECTED DRAWING: Figure 1

The present disclosure provides a patient system and method for interfacing with and controlling an oral medication dispensing device. The system registers the dispensing device to a particular patient and records biometric data regarding the patient. Upon verifying a dose schedule and biometric authentication of the patient, the system authorizes use of the medication dispensing device and causes an activator mechanism to activate. In doing so, an activator mechanism within the dispensing device moves a medication cartridge between a stored position and a dispensing position, where it can be compressed to safely and efficiently dispense medication to the patient.

Embodiments of the invention relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a GPRC5DxCD3 bispecific antibody according to a monthly administration schedule.

A non-transitory computer-readable storage medium, a user device, and a method configured to execute a program for managing a medical condition or treatment of a user are provided. When the procedure determines that the period of time for taking the predetermined dose has been exceeded by more than a lower threshold time, the procedure causes a late dose notification to be displayed. When a user interacts with the late dose notification, the program provides the user with an option to (i) indicate that they have taken the predetermined dose or (ii) indicate that they have not taken the predetermined dose. When the user indicates that they have taken the predetermined dose after the lower threshold time, the procedure provides the user with an option to (i) reset the current medicament administration schedule or (ii) maintain the current medicament administration schedule.

The invention relates to the cross field of toxicology and immunology, in particular to an intervention method for relieving T-2 toxin induced cellular immune aging based on PER2 protein inhibition and application of the intervention method. The method comprises the following steps: S1, providing an exposed object containing immune cells in an in-vitro culture system; s2, firstly applying a PER2 inhibitor; s3, sequentially finishing S2 and T-2 treatment according to a preset initial administration time interval; and S4, characterizing the Hippo pathway MST1 / YAP / p-YAP in 4 hours and / or 12 hours after T-2 treatment, and obtaining p-YAP subcellular localization, thereby determining or adjusting the administration time course. According to the scheme, closed-loop standard operation and parameter setting are carried out according to'administration-detection-time history determination '.

A pharmaceutical formulation in solid dosage form of a therapeutically effective amount of (R)-N-(1-hydroxypropan-2-yl)-5-(4-(trifluoromethyl)phenoxy)-2-naphthoamide is provided herein. A method for treating cancer is also provided herein, comprising a pharmaceutical formulation in solid dosage form of a therapeutically effective amount of (R)-N-(1-hydroxypropan-2-yl)-5-(4-(trifluoromethyl)phenoxy)-2-naphthoamide.

The present invention relates to dosing schedules for HER2 inhibitors useful in the prevention and / or treatment of cancer, in particular to doses thereof and / or the administration of a second or additional line.

Provided are improved dosing schedules and compositions for the intramuscular administration of compositions containing aromatase inhibitors such as letrozole, for use in treating letrozole-sensitive diseases, conditions or disorders. In the dosing schedules, a first dose of long-acting injectable composition is administered and after a delay period, a second dose of long-acting injectable composition is administered, which provides overlapping dosing periods and improves oestrogen suppression.

The present invention relates to a drug administration schedule for HER2 inhibitors useful in the prevention and / or treatment of cancer, particularly to their dosage and administration in second-line or subsequent lines.

Provided herein is an automated eye drop dispensing device that may feature an electromechanical actuation with closed-loop sensor control for precise medication delivery. The device may comprise a housing receiving a pump head assembly that threads directly onto standard eye drop bottles. An electromechanical actuator, coupled via a shuttle mechanism, may control pump chamber operation. A sensor system may monitor the dispensing tip to detect drop formation and release, enabling real-time closed-loop control that compensates for variations in medication properties and device orientation. The system may operate through a three-state sequence: detecting drop absence, formation, and release, automatically stopping upon successful dispensing. The device may include wireless communication for transmitting sensor-verified usage data to smartphone applications and healthcare systems. Additional features may include orientation sensors ensuring proper positioning, alignment aids with LED indicators, programmable dosing schedules, compatibility adapters for various bottle types, and integration with a companion mobile application.

The present invention relates to an improved method of reducing cytokine release syndrome following interruption of the administration plan of elicitumab for the treatment of CD20-expressing B cell cancers.

The present disclosure provides a physician system and method for interfacing with and controlling an oral medication dispensing device. The system registers a patient under the care of a doctor and records a dose schedule for the patient. The dose schedule specifies a particular medication and associated volume and timing interval for administration to the patient via a medication dispensing device. A medication cartridge is with the dose schedule. An invitation link is sent to the patient for the patient to link the physician system with their patient system and the medication dispensing device. The dose schedule can be pushed to the patient system to populate the patient system with the specifics of the dose schedule.

A non-transitory computer-readable storage medium is provided that includes instructions that, when executed by a computer, cause the computer to: execute a program for managing a medical condition or treatment of a user; monitoring a current administration schedule set within the program; determining whether the predetermined dose expires; determining an experience level of the user; in response to determining that the predetermined dose expires, generating a first notification alerting the user of the predetermined dose; and in response to detecting a user interaction with the first notification, providing a user interface that displays content related to the predetermined dose. At least a portion of the displayed content is based on an experience level of the user.

Providing a controlled-release formulation containing dorotaberine or its salts, or an active substance with a similar tendency to degrade through oxidation / hydrolysis. [Solution] The present invention provides a controlled-release formulation containing dorotaberine or a salt thereof, or an active substance with a similar tendency to degrade through oxidation / hydrolysis. The present invention provides a once- or twice-daily controlled-release formulation of dorotaberine or a salt thereof that avoids fluctuations in plasma levels, reduces pill burden and side effects through a simplified dosing schedule, and consequently improves patient compliance. The present invention also provides a method for preparing a controlled-release formulation of dorotaberine or a salt thereof. The present invention further provides a controlled-release formulation of dorotaberine or a salt thereof for the treatment of at least one symptom of gastrointestinal, biliary, urinary, and gynecological disorders characterized by a spastic state of smooth muscle in a subject.